BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19036233)

  • 1. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years.
    Berger GE; Proffitt TM; McConchie M; Kerr M; Markulev C; Yuen HP; O'Donnell C; Lubman D; Polari A; Wood S; Amminger PG; McGorry PD
    J Clin Psychiatry; 2008 Nov; 69(11):1702-14. PubMed ID: 19036233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects.
    Datto C; Berggren L; Patel JB; Eriksson H
    Clin Ther; 2009 Mar; 31(3):492-502. PubMed ID: 19393840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quetiapine in the treatment of acute mania: target dose for efficacious treatment.
    Vieta E; Goldberg JF; Mullen J; Vågerö M; Paulsson B
    J Affect Disord; 2007; 100 Suppl 1():S23-31. PubMed ID: 17382403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
    Paleacu D; Barak Y; Mirecky I; Mazeh D
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.
    De Deyn PP; Eriksson H; Svensson H;
    Int J Geriatr Psychiatry; 2012 Mar; 27(3):296-304. PubMed ID: 21538537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder.
    Honer WG; MacEwan GW; Gendron A; Stip E; Labelle A; Williams R; Eriksson H;
    J Clin Psychiatry; 2012 Jan; 73(1):13-20. PubMed ID: 21733490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder.
    Lindenmayer JP; Citrome L; Khan A; Kaushik S; Kaushik S
    J Clin Psychopharmacol; 2011 Apr; 31(2):160-8. PubMed ID: 21346616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.
    Vieta E; Calabrese JR; Goikolea JM; Raines S; Macfadden W;
    Bipolar Disord; 2007 Jun; 9(4):413-25. PubMed ID: 17547587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].
    György B; Robert K; László C; Andrea J;
    Neuropsychopharmacol Hung; 2008 Dec; 10(5):293-303. PubMed ID: 19419015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
    Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
    Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
    Buckley PF; Paulsson B; Brecher M
    J Affect Disord; 2007; 100 Suppl 1():S33-43. PubMed ID: 17376537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial.
    McIntyre RS; Brecher M; Paulsson B; Huizar K; Mullen J
    Eur Neuropsychopharmacol; 2005 Oct; 15(5):573-85. PubMed ID: 16139175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Devlin JW; Roberts RJ; Fong JJ; Skrobik Y; Riker RR; Hill NS; Robbins T; Garpestad E
    Crit Care Med; 2010 Feb; 38(2):419-27. PubMed ID: 19915454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study.
    Boidi G; Ferro M
    Hum Psychopharmacol; 2007 Jul; 22(5):299-306. PubMed ID: 17487936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.
    Fernandez HH; Okun MS; Rodriguez RL; Malaty IA; Romrell J; Sun A; Wu SS; Pillarisetty S; Nyathappa A; Eisenschenk S
    Int J Neurosci; 2009; 119(12):2196-205. PubMed ID: 19916848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of quetiapine for treatment of geriatric psychosis.
    Yang CH; Tsai SJ; Hwang JP
    J Psychopharmacol; 2005 Nov; 19(6):661-6. PubMed ID: 16272189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents.
    Swadi HS; Craig BJ; Pirwani NZ; Black VC; Buchan JC; Bobier CM
    Int Clin Psychopharmacol; 2010 Jan; 25(1):1-6. PubMed ID: 19809337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
    Byerly MJ; Nakonezny PA; Rush AJ
    Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies.
    Meulien D; Huizar K; Brecher M
    Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.